External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 4, 2011, Pages 1124-1130

  Burdick, Michael J ^a   Neumann, Donald ^a   Pohlman, Brad ^a   Reddy, Chandana A ^a   Tendulkar, Rahul D ^a   MacKlis, Roger ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Bulky disease; External beam radiotherapy; Follicular lymphoma; Positron emission tomography; Yttrium 90 ibritumomab tiuxetan

Indexed keywords

ANATOMICAL LOCATIONS; BULKY DISEASE; CLINICAL OUTCOME; COMBINED THERAPY; COMPLETE BLOOD COUNTS; COMPUTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FOLLICULAR LYMPHOMA; GROSS TUMOR VOLUME; HEMATOLOGIC TOXICITY; IBRITUMOMAB TIUXETAN; POSITRON EMISSION; PROGRESSION FREE SURVIVAL; YTTRIUM-90; YTTRIUM-90 IBRITUMOMAB TIUXETAN;

CHEMOTHERAPY; COMPUTERIZED TOMOGRAPHY; ELECTRONS; FAILURE ANALYSIS; ONCOLOGY; PATIENT MONITORING; PLATELETS; POSITRON EMISSION TOMOGRAPHY; POSITRONS; QUALITY ASSURANCE; RADIOTHERAPY; REFRACTORY MATERIALS; YTTRIUM;

YTTRIUM ALLOYS;

CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MITOXANTRONE; NAVELBINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BLOOD CELL COUNT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PLATELET COUNT; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; YTTRIUM RADIOISOTOPES;

EID: 79951958895     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.12.030     Document Type: Article

References (28)

1. A.D. Murtha, B.A. Rupnow, and J. Hansosn Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University Int J Radiat Oncol Biol Phys 49 2001 3 15 (Pubitemid 32041272)
2. R.B. Wilder, D. Jones, and S.L. Tucker Long-term results with radiotherapy for Stage I-II follicular lymphomas Int J Radiat Oncol Biol Phys 51 2001 1219 1227 (Pubitemid 33116314)
3. B.A. Guadagnolo, S. Li, and D. Neuberg Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy Int J Radiat Oncol Biol Phys 64 2006 928 934 (Pubitemid 43183595)
4. M.P. Mac Manus, and R.T. Hoppe Is radiotherapy curative for Stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University J Clin Oncol 14 1996 1282 1290 (Pubitemid 26105537)
5. D. Shan, J.A. Ledbetter, and O.W. Press Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 91 1998 1644 1652 (Pubitemid 28110329)
6. M.E. Reff, K. Carner, and K.S. Chambers Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435 445 (Pubitemid 24030569)
7. T.E. Witzig, I.W. Flinn, and L.I. Gordon Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma J Clin Oncol 20 2002 3262 3269 (Pubitemid 34831524)
8. K. Tobinai, T. Watanabe, and M. Ogura Japanese Phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma Cancer Sci 100 2009 158 164
9. T.E. Witzig, C.A. White, and G.A. Wiseman Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma J Clin Oncol 17 1999 3793 3803
10. T.E. Witzig, L.I. Gordon, and F. Cabanillas Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 20 2002 2453 2463 (Pubitemid 34525730)
11. G.A. Wiseman, L.I. Gordon, and P.S. Multani Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A Phase II multicenter trial Blood 99 2002 4336 4342 (Pubitemid 34627198)
12. T.E. Witzig, A. Molina, and L.I. Gordon Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan Cancer 109 2007 1804 1810 (Pubitemid 46668544)
13. R.I. Fisher, M.S. Kaminski, and R.L. Wahl Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas J Clin Oncol 23 2005 7565 7573 (Pubitemid 46291820)
14. A.S. Gokhale, J. Mayadev, B. Pohlman, and R.M. Macklis Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy Int J Radiat Oncol Biol Phys 63 2005 194 201 (Pubitemid 41583558)
15. T.E. Justice, J.A. Martenson, G.A. Wiseman, and T.E. Witzig Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy Cancer 107 2006 433 438 (Pubitemid 44036574)
16. B.D. Cheson, S.J. Horning, and B. Coiffier Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1999 1244
17. B.D. Cheson, B. Pfistner, and M.E. Juweid Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586 (Pubitemid 350002966)
18. G.A. Ulaner, P.M. Colletti, and P.S. Conti B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy - initial experience Radiology 246 2008 895 902
19. S.A. Jacobs, S.H. Swerdlow, and J. Kant Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma Clin Cancer Res 14 2008 7088 7094
20. A. Aviles, S. Delgado, and R. Fernandez Combined therapy in advanced Stages (III and IV) of follicular lymphoma increases the possibility of cure: Results of a large controlled clinical trial Eur J Haematol 68 2002 144 149 (Pubitemid 34620602)
21. E.J. Hall, and A.J. Giaccia Radiobiology for the radiologist 6th ed. 2006 Lippincott Williams & Wilkins Philadelphia
22. J.O. Armitage, P.P. Carbone, and J.M. Connors Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients J Clin Oncol 21 2003 897 906 (Pubitemid 46613489)
23. M.J. Burdick, and R. Macklis Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma Oncotargets Ther 2 2009 229 242
24. M. Lehnert, H. Ludwig, and N. Zojer Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma Oncotargets Ther 2 2009 199 208
25. J.D. Hainsworth, D.R. Spigel, and T.M. Markus Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a Phase II trial of the Sarah Cannon Oncology Research Constortium Clin Lymphoma Myeloma 9 2009 223 228
26. F. Morschhauser, J. Radford, and A. Van Hoof Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma J Clin Oncol 26 2008 5156 5164
27. P.L. Zinzani, M. Tani, and A. Pulsoni Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: A Phase II non-randomised trial (FLUMIZ) Lancet Oncol 9 2008 352 358
28. S. Montoto, A. Lopez-Guillermo, A. Altes, G. Perea, A. Ferrer, and M. Camos Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression Ann Oncol 15 2004 1484 1489 (Pubitemid 39409738)